Result:Very Good· Market: Down#Broad based#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 7.30 | 42.3% | 52.2% |
| Total Income | 7.57 | 38.4% | 56.5% |
| Expenditure | 7.30 | 58.6% | 53.1% |
| PBT | 0.27 | 68.8% | 287.1% |
| Net Profit | 0.22 | 60.8% | 946.5% |
| OPM | 5.18% | 14.35pp | 5.46pp |
| NPM | 2.92% | 7.37pp | 2.48pp |
| EPS | 0.44 | 60.4% | 1000.0% |
Small pharma company delivered strong core revenue growth (52.2% YoY) alongside a sharp adjusted PAT jump, but the prior-year base is very small so magnitude is discounted from top-of-band.
Informational and educational content only. Not investment advice.